60 Degrees Launches Central Location for Patient Enrollment in B-FREE Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 22 2025
0mins
Should l Buy SXTP?
Source: Yahoo Finance
Study Announcement: 60 Degrees Pharmaceuticals has opened patient enrollment for its B-FREE Chronic Babesiosis Study at the Cohen Center for Recovery from Complex Chronic Diseases, marking the first evaluation of a therapeutic for chronic babesiosis.
Study Details: The Phase 2 open-label study will assess the efficacy of the ARAKODA regimen of tafenoquine over 90 days, focusing on resolving severe fatigue and eradicating parasites in patients with chronic babesiosis.
Chronic Babesiosis Definition: Chronic babesiosis is characterized by disabling fatigue lasting at least six months, accompanied by other symptoms and laboratory confirmation of Babesia parasite exposure within the last year.
Regulatory Status: To date, no treatment for babesiosis has been approved by the U.S. Food and Drug Administration.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SXTP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SXTP
Wall Street analysts forecast SXTP stock price to rise
1 Analyst Rating
0 Buy
1 Hold
0 Sell
Hold
Current: 1.930
Low
3.40
Averages
3.40
High
3.40
Current: 1.930
Low
3.40
Averages
3.40
High
3.40
About SXTP
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
U.S. Stocks Rise in Morning Trading, Dow Up Over 100 Points
- Strong Dow Performance: The Dow Jones index rose over 100 points on Monday, gaining 0.33% to reach 49,259.65, reflecting optimistic market sentiment regarding economic recovery.
- Steel Sector Earnings Miss: Steel Dynamics Inc. reported Q4 earnings of $1.82 per share, missing the $1.95 consensus estimate, with sales of $4.414 billion also falling short of the $4.575 billion forecast, indicating challenges within the industry.
- Oil and Gas Stocks Surge: Battalion Oil Corp. shares skyrocketed 379% to $6.13 after switching gas processing partners and boosting production, while Brand Engagement Network Inc. surged 196% to $48.79 following a strategic partnership announcement, highlighting strong investor interest.
- Economic Data Improvement: U.S. durable goods orders rose 5.3% month-over-month in November, exceeding the 3.7% market estimate, following a revised 2.1% decline in October, suggesting a gradual recovery in economic activity.
See More
Baker Hughes Q4 Earnings Exceed Expectations
- Earnings Beat: Baker Hughes reported adjusted earnings of 78 cents per share for Q4, surpassing market expectations of 67 cents, indicating strong performance in the oil and gas sector, which is likely to boost investor confidence.
- Sales Growth: The company's quarterly sales reached $7.386 billion, exceeding expectations of $7.068 billion, reflecting its competitive edge amid recovering market demand and potentially driving future business expansion.
- Stock Price Surge: Baker Hughes shares rose 3.7% to $55.81 in pre-market trading, indicating a positive market reaction to its financial performance, which may attract more investor interest.
- Industry Impact: This earnings improvement not only strengthens Baker Hughes' market position but could also positively influence the entire oil and gas industry, prompting other companies to increase investment and innovation efforts.
See More
Abbott Laboratories (ABT) Reports Q4 Sales Below Expectations, Stock Drops 7%
- Sales Performance Miss: Abbott Laboratories reported Q4 2025 sales of $11.46 billion, slightly below the consensus estimate of $11.80 billion, with a 4.4% increase in sales but only 3% organic growth, indicating competitive pressure in the market.
- Earnings Outlook Disappointment: Although adjusted earnings per share of $1.50 met Wall Street expectations, the overall performance failed to boost investor confidence, resulting in a stock drop of over 7% on Thursday, reflecting concerns about future growth.
- Market Reaction Intense: Following Abbott's earnings report, the significant stock decline illustrates investor pessimism regarding the company's future performance, which may impact its market position in the MedTech sector.
- Industry Impact Significant: Abbott's disappointing results could trigger a ripple effect across the MedTech industry, prompting investors to reassess the financial health of other related companies, potentially leading to overall valuation fluctuations in the sector.
See More
60 Degrees Pharmaceuticals (SXTP) Partners with Runway Health to Launch Arakoda, Stock Surges 161%
- Partnership Launch: 60 Degrees Pharmaceuticals' collaboration with Runway Health will officially commence on April 2, 2026, aiming to provide international travelers access to Arakoda through personalized medical plans, enhancing travel safety.
- Market Reaction: Following the partnership announcement, 60 Degrees' stock surged over 161% in Thursday's pre-market trading, reflecting strong investor confidence in the company's growth potential.
- Product Uniqueness: Arakoda is the only broad-spectrum, once-weekly malaria prevention option approved by the FDA in the U.S., addressing the urgent need for effective preventive measures among international travelers and solidifying the company's market position.
- Enhanced User Experience: Through Runway Health's telehealth platform, travelers can consult with healthcare providers online before departure and receive home delivery of medications, significantly improving user convenience and accessibility to medical services.
See More
Procter & Gamble (PG) Stock Rises 2% After Beating EPS Estimates in Mixed Q2 Results
- Market Uptrend: U.S. stocks traded higher this morning, with the Dow Jones gaining around 300 points, or 0.63%, reflecting optimistic sentiment towards economic recovery, which may attract more investor interest.
- P&G's Strong Performance: Procter & Gamble reported Q2 adjusted EPS of $1.88, beating the analyst consensus of $1.86, although quarterly sales of $22.208 billion fell short of the expected $22.282 billion, indicating the company's efforts in cost control amidst mixed results.
- Notable Stock Surges: Shares of 60 Degrees Pharmaceuticals skyrocketed 297% to $7.94 after announcing a partnership with Runway Health to expand pre-departure access to ARAKODA, demonstrating strong market reaction to new collaborations.
- Energy Sector Decline: Despite the overall market rise, energy stocks dipped 0.4% on Wednesday, suggesting potential challenges in supply-demand balance within the sector, prompting investors to monitor future market dynamics.
See More
60 Degree Pharmaceuticals (SXTP) Announces 1-for-4 Reverse Stock Split to Regain Nasdaq Compliance
- Reverse Stock Split: 60 Degree Pharmaceuticals plans to implement a 1-for-4 reverse stock split effective January 20, 2026, aimed at regaining compliance with Nasdaq's minimum bid price requirement and stabilizing its capital market position.
- Shareholder Approval: The plan received shareholder approval at a special meeting in October 2025 and subsequent board authorization in December, reflecting strategic decision-making supported by shareholders.
- Reduction in Shares: The reverse split will reduce the number of outstanding shares from approximately 5.15 million to about 1.29 million, with no change to the stock's par value or authorized share count, ensuring minimal impact on shareholders' percentage ownership.
- Market Performance: SXTP has traded between $0.34 and $6 over the past year, closing yesterday at $0.46, down 2.39%, and the reverse split is expected to enhance market confidence and attract investor interest.
See More
U.S. Stocks Rise in Morning Trading, Dow Up Over 100 Points
- Strong Dow Performance: The Dow Jones index rose over 100 points on Monday, gaining 0.33% to reach 49,259.65, reflecting optimistic market sentiment regarding economic recovery.
- Steel Sector Earnings Miss: Steel Dynamics Inc. reported Q4 earnings of $1.82 per share, missing the $1.95 consensus estimate, with sales of $4.414 billion also falling short of the $4.575 billion forecast, indicating challenges within the industry.
- Oil and Gas Stocks Surge: Battalion Oil Corp. shares skyrocketed 379% to $6.13 after switching gas processing partners and boosting production, while Brand Engagement Network Inc. surged 196% to $48.79 following a strategic partnership announcement, highlighting strong investor interest.
- Economic Data Improvement: U.S. durable goods orders rose 5.3% month-over-month in November, exceeding the 3.7% market estimate, following a revised 2.1% decline in October, suggesting a gradual recovery in economic activity.
See More
Baker Hughes Q4 Earnings Exceed Expectations
- Earnings Beat: Baker Hughes reported adjusted earnings of 78 cents per share for Q4, surpassing market expectations of 67 cents, indicating strong performance in the oil and gas sector, which is likely to boost investor confidence.
- Sales Growth: The company's quarterly sales reached $7.386 billion, exceeding expectations of $7.068 billion, reflecting its competitive edge amid recovering market demand and potentially driving future business expansion.
- Stock Price Surge: Baker Hughes shares rose 3.7% to $55.81 in pre-market trading, indicating a positive market reaction to its financial performance, which may attract more investor interest.
- Industry Impact: This earnings improvement not only strengthens Baker Hughes' market position but could also positively influence the entire oil and gas industry, prompting other companies to increase investment and innovation efforts.
See More
Abbott Laboratories (ABT) Reports Q4 Sales Below Expectations, Stock Drops 7%
- Sales Performance Miss: Abbott Laboratories reported Q4 2025 sales of $11.46 billion, slightly below the consensus estimate of $11.80 billion, with a 4.4% increase in sales but only 3% organic growth, indicating competitive pressure in the market.
- Earnings Outlook Disappointment: Although adjusted earnings per share of $1.50 met Wall Street expectations, the overall performance failed to boost investor confidence, resulting in a stock drop of over 7% on Thursday, reflecting concerns about future growth.
- Market Reaction Intense: Following Abbott's earnings report, the significant stock decline illustrates investor pessimism regarding the company's future performance, which may impact its market position in the MedTech sector.
- Industry Impact Significant: Abbott's disappointing results could trigger a ripple effect across the MedTech industry, prompting investors to reassess the financial health of other related companies, potentially leading to overall valuation fluctuations in the sector.
See More
60 Degrees Pharmaceuticals (SXTP) Partners with Runway Health to Launch Arakoda, Stock Surges 161%
- Partnership Launch: 60 Degrees Pharmaceuticals' collaboration with Runway Health will officially commence on April 2, 2026, aiming to provide international travelers access to Arakoda through personalized medical plans, enhancing travel safety.
- Market Reaction: Following the partnership announcement, 60 Degrees' stock surged over 161% in Thursday's pre-market trading, reflecting strong investor confidence in the company's growth potential.
- Product Uniqueness: Arakoda is the only broad-spectrum, once-weekly malaria prevention option approved by the FDA in the U.S., addressing the urgent need for effective preventive measures among international travelers and solidifying the company's market position.
- Enhanced User Experience: Through Runway Health's telehealth platform, travelers can consult with healthcare providers online before departure and receive home delivery of medications, significantly improving user convenience and accessibility to medical services.
See More
Procter & Gamble (PG) Stock Rises 2% After Beating EPS Estimates in Mixed Q2 Results
- Market Uptrend: U.S. stocks traded higher this morning, with the Dow Jones gaining around 300 points, or 0.63%, reflecting optimistic sentiment towards economic recovery, which may attract more investor interest.
- P&G's Strong Performance: Procter & Gamble reported Q2 adjusted EPS of $1.88, beating the analyst consensus of $1.86, although quarterly sales of $22.208 billion fell short of the expected $22.282 billion, indicating the company's efforts in cost control amidst mixed results.
- Notable Stock Surges: Shares of 60 Degrees Pharmaceuticals skyrocketed 297% to $7.94 after announcing a partnership with Runway Health to expand pre-departure access to ARAKODA, demonstrating strong market reaction to new collaborations.
- Energy Sector Decline: Despite the overall market rise, energy stocks dipped 0.4% on Wednesday, suggesting potential challenges in supply-demand balance within the sector, prompting investors to monitor future market dynamics.
See More
60 Degree Pharmaceuticals (SXTP) Announces 1-for-4 Reverse Stock Split to Regain Nasdaq Compliance
- Reverse Stock Split: 60 Degree Pharmaceuticals plans to implement a 1-for-4 reverse stock split effective January 20, 2026, aimed at regaining compliance with Nasdaq's minimum bid price requirement and stabilizing its capital market position.
- Shareholder Approval: The plan received shareholder approval at a special meeting in October 2025 and subsequent board authorization in December, reflecting strategic decision-making supported by shareholders.
- Reduction in Shares: The reverse split will reduce the number of outstanding shares from approximately 5.15 million to about 1.29 million, with no change to the stock's par value or authorized share count, ensuring minimal impact on shareholders' percentage ownership.
- Market Performance: SXTP has traded between $0.34 and $6 over the past year, closing yesterday at $0.46, down 2.39%, and the reverse split is expected to enhance market confidence and attract investor interest.
See More
